Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Short-Term Debt: ¥188.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605177 Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
62 GF Score
Price ¥24.73
GF Value ¥19.24
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Zhejiang East-Asia Pharmaceutical Co Short-Term Debt?

Zhejiang East-Asia Pharmaceutical Co SHSE:605177 +0.16% 62 Short-Term Debt is ¥188.2 Mil as of Jun. 2026. GuruFocus rates SHSE:605177 with a GF Score™ of 62/100 and a GF Value™ of ¥19.24 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Zhejiang East-Asia Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥188.2 Mil.

Zhejiang East-Asia Pharmaceutical Co's quarterly Short-Term Debt declined from Dec. 2025 (¥324.6 Mil) to Mar. 2026 (¥236.1 Mil) and declined from Mar. 2026 (¥236.1 Mil) to Jun. 2026 (¥188.2 Mil).

Zhejiang East-Asia Pharmaceutical Co's annual Short-Term Debt increased from Dec. 2023 (¥363.0 Mil) to Dec. 2024 (¥474.9 Mil) but then declined from Dec. 2024 (¥474.9 Mil) to Dec. 2025 (¥324.6 Mil).

Zhejiang East-Asia Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zhejiang East-Asia Pharmaceutical Co Short-Term Debt Related Terms

Zhejiang East-Asia Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang East-Asia Pharmaceutical Co Short-Term Debt Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only 218.90 233.14 363.01 474.90 324.61

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 534.54 411.49 324.61 236.11 188.22
SHSE:605177
62GF Score
Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥188.2 Mil mean?
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Short-Term Debt of ¥188.2 Mil as of Jun. 2026.
Is Zhejiang East-Asia Pharmaceutical Co's Short-Term Debt too high?
Zhejiang East-Asia Pharmaceutical Co's current Short-Term Debt is ¥188.2 Mil. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Short-Term Debt compare to VRTX and REGN?
Zhejiang East-Asia Pharmaceutical Co's Short-Term Debt of ¥188.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Zhejiang East-Asia Pharmaceutical Co's current Short-Term Debt is ¥188.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.24, compared to a current price of ¥24.73 — trading 28.5% above its estimated fair value. The current Short-Term Debt is ¥188.2 Mil. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Short-Term Debt is ¥188.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.73 is trading 28.5% above its estimated GF Value™ of ¥19.24. GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:605177:

  • Short-Term Debt: ¥188.2 Mil
  • GF Value™: ¥19.24 vs. price of ¥24.73 (28.5% above fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang East-Asia Pharmaceutical Co Business Description

Address No. 118, Laodong North Road, 23rd Floor, Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
62GF Score

Get the complete analysis for SHSE:605177

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.73
Price
¥19.24
GF Value